Literature DB >> 311819

Immunoglobulin subclass-specific immunodeficiency in mice with an X-linked B-lymphocyte defect.

R M Perlmutter, M Nahm, K E Stein, J Slack, I Zitron, W E Paul, J M Davie.   

Abstract

CBA/N mice express an X-linked deficiency in their antibody response to many bacterial carbohydrates; we have shown recently that these antigens normally elicit antibody responses predominantly of the IgM and IgG3 isotypes. Here we demonstrate that mice, with the CBA/N phenotype have perferential deficiencies of IgM and IgG3 immunoglobulin expression, both when measured in serum and in cells secreting these isotypes, and that this deficiency is only partially corrected by polyclonal activation of B cells. This suggests that CBA/N mice may lack a subpopulation of B cells that contain most of the IgG3 precursors.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 311819      PMCID: PMC2184855          DOI: 10.1084/jem.149.4.993

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  14 in total

Review 1.  Surface immunoglobulin D as a functional receptor for a subclass of B lymphocytes.

Authors:  D E Mosier; I M Zitron; J J Mond; A Ahmed; I Scher; W E Paul
Journal:  Immunol Rev       Date:  1977       Impact factor: 12.988

2.  The "patchy" immunodeficiency of CBA/N mice.

Authors:  J Quintáns
Journal:  Eur J Immunol       Date:  1977-10       Impact factor: 5.532

3.  A plaque assay for all cells secreting Ig of a given type or class.

Authors:  E Gronowicz; A Coutinho; F Melchers
Journal:  Eur J Immunol       Date:  1976-08       Impact factor: 5.532

4.  T-independent responses in B cell-defective CBA/N mice to Brucella abortus and to trinitrophenyl (TNP) conjugates of Brucella abortus.

Authors:  J J Mond; I Scher; D E Mosier; M Baese; W E Paul
Journal:  Eur J Immunol       Date:  1978-07       Impact factor: 5.532

5.  In vitro responses of CBA/N mice: spleen cells of mice with an X-linked defect that precludes immune responses to several thymus-independent antigens can respond to TNP-lipopolysaccharide.

Authors:  D E Mosier; I Scher; W E Paul
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

6.  Analysis of the diversity of murine antibodies to dextran B1355. III. Idiotypic and spectrotypic correlations.

Authors:  D Hansburg; R M Perlmutter; D E Briles; J M Davie
Journal:  Eur J Immunol       Date:  1978-05       Impact factor: 5.532

7.  Subclass restriction of murine anti-carbohydrate antibodies.

Authors:  R M Perlmutter; D Hansburg; D E Briles; R A Nicolotti; J M Davie
Journal:  J Immunol       Date:  1978-08       Impact factor: 5.422

8.  Cellular and molecular requirements for X-linked, hapten-specific B-cell blockade in CBA/N mice.

Authors:  B Merchant; H Snippe; E F Lizzio; J K Inman
Journal:  J Exp Med       Date:  1978-06-01       Impact factor: 14.307

9.  Immunological unresponsiveness to thymus-independent antigens: two fundamentally different genetic mechanisms of B-cell unresponsiveness to dextran.

Authors:  C Fernandez; G Möller
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

10.  Inability of mice with a defect in B-lymphocyte maturation to respond to phosphorycholine on immunogenic carriers.

Authors:  J J Mond; R Lieberman; J K Inman; D E Mosier; W E Paul
Journal:  J Exp Med       Date:  1977-10-01       Impact factor: 14.307

View more
  31 in total

1.  X-chromosome-linked immune-deficient mice have B-1b cells.

Authors:  J Riggs; K Howell; B Matechin; R Matlack; A Pennello; R Chiasson
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

2.  The role of Bruton's tyrosine kinase in the development and BCR/TLR-dependent activation of AM14 rheumatoid factor B cells.

Authors:  Kerstin Nündel; Patricia Busto; Michelle Debatis; Ann Marshak-Rothstein
Journal:  J Leukoc Biol       Date:  2013-06-26       Impact factor: 4.962

3.  A novel Tth111I restriction fragment length polymorphism (RFLP) allows tracing of X-chromosome inactivation in the (Xid) heterozygote.

Authors:  V Shanmugam; V M Chapman; K W Sell; B K Saha
Journal:  Biochem Genet       Date:  1996-02       Impact factor: 1.890

4.  Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects.

Authors:  H Yesid Estupiñán; Thibault Bouderlique; Chenfei He; Anna Berglöf; Dhanu Gupta; Osama Saher; Miguel Ángel Daza Cruz; Lucia Peña-Perez; Liang Yu; Rula Zain; Mikael C I Karlsson; Robert Månsson; C I Edvard Smith
Journal:  Blood Adv       Date:  2020-06-09

5.  Localization of spontaneously hyperactive B cells of NZB mice to a specific B cell subset.

Authors:  P B Nakajima; S K Datta; R S Schwartz; B T Huber
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

6.  Monoclonal antibodies to mouse antigens. II. Characterization of thirty-one anti-I-J reagents.

Authors:  V Hauptfeld; J A Kapp; K Frederick; J Trial; D C Shreffler
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

7.  Chronic giardiasis in B-cell-deficient mice expressing the xid gene.

Authors:  D P Snider; D Skea; B J Underdown
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

8.  Opposing effects of xid and nu mutations on proliferative and polyclonal antibody and autoantibody responses to peptidoglycan, LPS, protein A and PWM.

Authors:  R Dziarski
Journal:  Immunology       Date:  1984-11       Impact factor: 7.397

9.  Natural anti-intestinal goblet cell autoantibody production from marginal zone B cells.

Authors:  Daiju Ichikawa; Masanao Asano; Susan A Shinton; Joni Brill-Dashoff; Anthony M Formica; Anna Velcich; Richard R Hardy; Kyoko Hayakawa
Journal:  J Immunol       Date:  2014-12-05       Impact factor: 5.422

10.  Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae.

Authors:  D E Briles; M Nahm; K Schroer; J Davie; P Baker; J Kearney; R Barletta
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.